Bjarne Winther Kristensen

List of Publications by Year in Descending Order

124 papers	4,458 citations	36 h-index	64 g-index
146 ext. papers	5,824 ext. citations	5.2 avg, IF	5.37 L-index

#	Paper	IF	Citations
124	Letter to the Editor. Copenhagen grading of meningioma.. *Journal of Neurosurgery*, **2022**, 1-3	3.2	
123	Preclinical cerebral cryoablation in non-tumor bearing pigs.. *Scientific Reports*, **2022**, 12, 1977	4.9	0
122	Fluorescein-guided resection of cerebral metastases is associated with greater tumor resection. *Acta Neurochirurgica*, **2021**, 1	3	5
121	The multi-target small-molecule inhibitor SB747651A shows in vitro and in vivo anticancer efficacy in glioblastomas. *Scientific Reports*, **2021**, 11, 6066	4.9	3
120	The Prognostic Value of Methylation Signatures and Mutations in Atypical Meningiomas. *Cancers*, **2021**, 13,	6.6	2
119	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. *Acta Neuropathologica*, **2021**, 142, 179-189	14.3	5
118	Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas. *Journal of Neuropathology and Experimental Neurology*, **2021**, 80, 541-551	3.1	1
117	Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches. *Acta Neuropathologica Communications*, **2021**, 9, 101	7.3	9
116	Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics. *Neuropathology and Applied Neurobiology*, **2021**, 47, 108-126	5.2	3
115	The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. *Brain Pathology*, **2021**, 31, e12921	6	1
114	Asymmetric cell division promotes therapeutic resistance in glioblastoma stem cells. *JCI Insight*, **2021**, 6,	9.9	3
113	Microglia-Secreted Factors Enhance Dopaminergic Differentiation of Tissue- and iPSC-Derived Human Neural Stem Cells. *Stem Cell Reports*, **2021**, 16, 281-294	8	4
112	Tumor-Associated Microglia and Macrophages in the Glioblastoma Microenvironment and Their Implications for Therapy. *Cancers*, **2021**, 13,	6.6	9
111	Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas. *Neuropathology and Applied Neurobiology*, **2021**,	5.2	1
110	Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. *Scientific Reports*, **2021**, 11, 17918	4.9	1
109	AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. *Nature Communications*, **2020**, 11, 6366	17.4	8
108	Characterization of the TNF and IL-1 systems in human brain and blood after ischemic stroke. *Acta Neuropathologica Communications*, **2020**, 8, 81	7.3	21

107	Sodium fluorescein shows high surgeon-reported usability in glioblastoma surgery. *Journal of the Royal College of Surgeons of Edinburgh*, **2020**, 18, 344-348	2.5	6
106	Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. *Journal of Neuro-Oncology*, **2020**, 147, 1-14	4.8	7
105	The risk of developing seizures before and after surgery for brain metastases. *Clinical Neurology and Neurosurgery*, **2020**, 193, 105779	2	2
104	Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner. *Cancer Discovery*, **2020**, 10, 1210-1225	24.4	49
103	Spatial and phenotypic characterization of pancreatic cancer-associated fibroblasts after neoadjuvant treatment. *Histology and Histopathology*, **2020**, 35, 811-825	1.4	6
102	Endoscopic vs. microscopic transsphenoidal pituitary surgery: a single centre study. *Scientific Reports*, **2020**, 10, 21942	4.9	6
101	Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas. *Scientific Reports*, **2020**, 10, 9285	4.9	2
100	Multiple formin proteins participate in glioblastoma migration. *BMC Cancer*, **2020**, 20, 710	4.8	9
99	Expression Profiling of Primary and Recurrent Glioblastomas Reveals a Reduced Level of Pentraxin 3 in Recurrent Glioblastomas. *Journal of Neuropathology and Experimental Neurology*, **2020**, 79, 975-985	3.1	1
98	Do we really know who has an methylated glioma? Results of an international survey regarding use of analyses for glioma. *Neuro-Oncology Practice*, **2020**, 7, 68-76	2.2	12
97	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. *Acta Neuropathologica*, **2019**, 138, 497-504	14.3	36
96	Molecular pathology of tumors of the central nervous system. *Annals of Oncology*, **2019**, 30, 1265-1278	10.3	63
95	Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival. *Journal of Neuropathology and Experimental Neurology*, **2019**, 78, 633-640	3.1	8
94	Frameless stereotactic neuronavigated biopsy: A retrospective study of morbidity, diagnostic yield, and the potential of fluorescence: A single-center clinical investigation. *Clinical Neurology and Neurosurgery*, **2019**, 181, 28-32	2	2
93	A tumorsphere model of glioblastoma multiforme with intratumoral heterogeneity for quantitative analysis of cellular migration and drug response. *Experimental Cell Research*, **2019**, 379, 73-82	4.2	9
92	Comparison of 5-aminolevulinic acid and sodium fluorescein for intraoperative tumor visualization in patients with high-grade gliomas: a single-center retrospective study. *Journal of Neurosurgery*, **2019**, 1-8	3.2	10
91	Early postoperative MRI after resection of brain metastases-complete tumour resection associated with prolonged survival. *Acta Neurochirurgica*, **2019**, 161, 555-565	3	10
90	Nonhypoxic pharmacological stabilization of Hypoxia Inducible Factor 1Effects on dopaminergic differentiation of human neural stem cells. *European Journal of Neuroscience*, **2019**, 49, 497-509	3.5	1

89	Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines. *Pathology and Oncology Research*, **2019**, 25, 59-69	2.6	3
88	High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma. *Journal of Neuro-Oncology*, **2018**, 138, 49-53	4.8	25
87	Heterogenic expression of stem cell markers in patient-derived glioblastoma spheroid cultures exposed to long-term hypoxia. *CNS Oncology*, **2018**, 7, CNS15	4	6
86	DNA methylation-based classification of central nervous system tumours. *Nature*, **2018**, 555, 469-474	50.4	992
85	Hereditary spastic paraplegia type 8: Neuropathological findings. *Brain Pathology*, **2018**, 28, 292-294	6	1
84	Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. *Neuropathology and Applied Neurobiology*, **2018**, 44, 172-184	5.2	20
83	Omics-Based Approach Reveals Complement-Mediated Inflammation in Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). *Frontiers in Immunology*, **2018**, 9, 741	8.4	5
82	Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification. *Diagnostic Pathology*, **2018**, 13, 38	3	14
81	D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells. *Clinical Cancer Research*, **2018**, 24, 5381-5391	12.9	25
80	Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas. *BMC Cancer*, **2018**, 18, 270	4.8	13
79	Intermittent, low dose carbon monoxide exposure enhances survival and dopaminergic differentiation of human neural stem cells. *PLoS ONE*, **2018**, 13, e0191207	3.7	14
78	SuperQuant-assisted comparative proteome analysis of glioblastoma subpopulations allows for identification of potential novel therapeutic targets and cell markers. *Oncotarget*, **2018**, 9, 9400-9414	3.3	6
77	Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. *Neuropathology and Applied Neurobiology*, **2018**, 44, 185-206	5.2	105
76	Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. *JCI Insight*, **2018**, 3,	9.9	85
75	Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. *Scientific Reports*, **2018**, 8, 14965	4.9	3
74	Intraoperative low field MRI in transsphenoidal pituitary surgery. *Endocrine Connections*, **2018**, 7, 897-906	3.5	4
73	Spontaneous ischaemic stroke lesions in a dog brain: neuropathological characterisation and comparison to human ischaemic stroke. *Acta Veterinaria Scandinavica*, **2017**, 59, 7	2	9
72	Shift of microRNA profile upon glioma cell migration using patient-derived spheroids and serum-free conditions. *Journal of Neuro-Oncology*, **2017**, 132, 45-54	4.8	13

71	Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo. *BMC Cancer*, **2017**, 17, 178	4.8	16
70	The gene expression and immunohistochemical time-course of diphenylcyclopropenone-induced contact allergy in healthy humans following repeated epicutaneous challenges. *Experimental Dermatology*, **2017**, 26, 926-933	4	5
69	Patterns of diagnostic marker assessment in adult diffuse glioma: a survey of the European Confederation of Neuropathological Societies (Euro-CNS) **2017**, 36 (2017), 5-14		6
68	Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. *Acta Oncologica*, **2017**, 56, 1776-1785	3.2	11
67	Expression and prognostic value of JAM-A in gliomas. *Journal of Neuro-Oncology*, **2017**, 135, 107-117	4.8	8
66	Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas. *PLoS ONE*, **2017**, 12, e0172234	3.7	42
65	APNG as a prognostic marker in patients with glioblastoma. *PLoS ONE*, **2017**, 12, e0178693	3.7	8
64	Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. *PLoS ONE*, **2017**, 12, e0182954	3.7	36
63	A 4-miRNA signature to predict survival in glioblastomas. *PLoS ONE*, **2017**, 12, e0188090	3.7	16
62	Convection-enhanced delivery of an anti-miR is well-tolerated, preserves anti-miR stability and causes efficient target de-repression: a proof of concept. *Journal of Neuro-Oncology*, **2016**, 126, 47-55	4.8	21
61	Trends in tumors in the central nervous system in elderly in Denmark, 2008-2012. *Acta Oncologica*, **2016**, 55 Suppl 1, 91-7	3.2	9
60	Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1824-36	8.8	8
59	Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke. *Acta Neuropathologica*, **2016**, 131, 775-91	14.3	46
58	Expression and prognostic value of the WEE1 kinase in gliomas. *Journal of Neuro-Oncology*, **2016**, 127, 381-9	4.8	39
57	miR-21 Is Linked to Glioma Angiogenesis: A Co-Localization Study. *Journal of Histochemistry and Cytochemistry*, **2016**, 64, 138-48	3.4	46
56	Establishment and Characterization of a Tumor Stem Cell-Based Glioblastoma Invasion Model. *PLoS ONE*, **2016**, 11, e0159746	3.7	21
55	Highly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenograft Model using Convection-Enhanced Delivery. *Theranostics*, **2016**, 6, 2278-2291	12.1	15
54	Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. *PLoS ONE*, **2016**, 11, e0155106	3.7	21

53	Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors. *PLoS ONE*, **2016**, 11, e0169129	3.7	11
52	Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. *Stem Cells*, **2016**, 34, 2026-39	5.8	133
51	Widespread inflammation in CLIPPERS syndrome indicated by autopsy and ultra-high-field 7T MRI. *Neurology: Neuroimmunology and NeuroInflammation*, **2016**, 3, e226	9.1	33
50	Conditional ablation of myeloid TNF increases lesion volume after experimental stroke in mice, possibly via altered ERK1/2 signaling. *Scientific Reports*, **2016**, 6, 29291	4.9	23
49	Shift of microRNA profile upon orthotopic xenografting of glioblastoma spheroid cultures. *Journal of Neuro-Oncology*, **2016**, 128, 395-404	4.8	5
48	Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients. *Journal of Neuro-Oncology*, **2016**, 130, 439-448	4.8	3
47	Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting. *Journal of Neuro-Oncology*, **2016**, 130, 53-62	4.8	24
46	Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. *Advances in Experimental Medicine and Biology*, **2015**, 853, 111-38	3.6	36
45	High levels of c-Met is associated with poor prognosis in glioblastoma. *Journal of Neuro-Oncology*, **2015**, 122, 517-27	4.8	47
44	Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. *Cancer Cell*, **2015**, 28, 441-455	24.3	160
43	Estimation of Tumor Volumes by 11C-MeAIB and 18F-FDG PET in an Orthotopic Glioblastoma Rat Model. *Journal of Nuclear Medicine*, **2015**, 56, 1562-8	8.9	8
42	Systemic physiology and neuroapoptotic profiles in young and adult rats exposed to surgery: A randomized controlled study comprising four different anaesthetic techniques. *International Journal of Developmental Neuroscience*, **2015**, 45, 11-8	2.7	7
41	STEM-13EXPRESSION OF STEM CELL, PROLIFERATION AND CHEMORESISTANCE MARKERS IN GLIOMA CELLS IN THE TUMOR PERIPHERY. *Neuro-Oncology*, **2015**, 17, v210.5-v211	1	78
40	TMIC-18TUMOR-ASSOCIATED MICROGLIA/MACROPHAGES ARE ASSOCIATED WITH POOR PROGNOSIS IN HIGH-GRADE GLIOMAS AND CONTRIBUTE TO THE GLIOBLASTOMA STEM CELL-LIKE NICHES. *Neuro-Oncology*, **2015**, 17, v218.6-v218	1	78
39	Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study. *British Journal of Clinical Pharmacology*, **2015**, 79, 677-84	3.8	14
38	Determining viability of using APNG status as a prognostic marker in patients with glioblastoma multiforme.. *Journal of Clinical Oncology*, **2015**, 33, 2028-2028	2.2	
37	No effect of ablation of surfactant protein-D on acute cerebral infarction in mice. *Journal of Neuroinflammation*, **2014**, 11, 123	10.1	16
36	Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. *CNS Oncology*, **2014**, 3, 287-98	4	8

35	MR-03MicroRNA PROFILE OF MIGRATING GLIOBLASTOMA CELLS KEPT IN STEM CELL MEDIUM. *Neuro-Oncology*, **2014**, 16, v125-v125	1	78
34	Clinical value of CD133 and nestin in patients with glioma: a population-based study. *International Journal of Clinical and Experimental Pathology*, **2014**, 7, 3739-51	1.4	39
33	A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). *Journal of Neuro-Oncology*, **2013**, 114, 309-17	4.8	29
32	MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. *Journal of Neuro-Oncology*, **2013**, 111, 71-81	4.8	80
31	Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2Qdeoxycytidine and interferon-Ltreatments: results from a multicentric study. *American Journal of Pathology*, **2013**, 182, 540-52	5.8	48
30	MicroRNA biomarkers in glioblastoma. *Journal of Neuro-Oncology*, **2013**, 114, 13-23	4.8	45
29	Prognostic value of Musashi-1 in gliomas. *Journal of Neuro-Oncology*, **2013**, 115, 453-61	4.8	36
28	Glioma spheroids obtained via ultrasonic aspiration are viable and express stem cell markers: a new tissue resource for glioma research. *Neurosurgery*, **2013**, 73, 868-86; discussion 886	3.2	20
27	A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1. *International Journal of Clinical and Experimental Pathology*, **2013**, 6, 31-40	1.4	28
26	What is the clinical value of cancer stem cell markers in gliomas?. *International Journal of Clinical and Experimental Pathology*, **2013**, 6, 334-48	1.4	57
25	Invasion of primary glioma- and cell line-derived spheroids implanted into corticostriatal slice cultures. *International Journal of Clinical and Experimental Pathology*, **2013**, 6, 546-60	1.4	29
24	C-met, a new prognostic biomarker in glioblastoma multiforme.. *Journal of Clinical Oncology*, **2013**, 31, 2088-2088	2.2	
23	Small cell glioblastoma or small cell carcinoma: a case report and review of the literature **2013**, 32, 303-10		0
22	Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers. *Neurotoxicity Research*, **2012**, 22, 43-58	4.3	10
21	Primary Glioma Spheroids: Advantage of Serum-Free Medium **2012**, 83-91		
20	Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. *Journal of Neuro-Oncology*, **2011**, 103, 43-58	4.8	96
19	CD133+ niches and single cells in glioblastoma have different phenotypes. *Journal of Neuro-Oncology*, **2011**, 104, 129-43	4.8	47
18	Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. *Journal of Histochemistry and Cytochemistry*, **2011**, 59, 391-407	3.4	63

17	Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. *Neurosurgery*, **2010**, 66, 933-47	3.2	43
16	Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. *Journal of Neuro-Oncology*, **2009**, 95, 117-128	4.8	60
15	CD133 identifies perivascular niches in grade II-IV astrocytomas. *Journal of Neuro-Oncology*, **2008**, 90, 157-70	4.8	87
14	Long-term, repeated dose in vitro neurotoxicity of the glutamate receptor antagonist L-AP3, demonstrated in rat hippocampal slice cultures by using continuous propidium iodide incubation. *ATLA Alternatives To Laboratory Animals*, **2007**, 35, 211-21	2.1	4
13	Toxic effects of lipid-mediated gene transfer in ventral mesencephalic explant cultures. *Basic and Clinical Pharmacology and Toxicology*, **2006**, 98, 395-400	3.1	27
12	Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair. *CNS and Neurological Disorders*, **2005**, 4, 435-52		161
11	Colchicine induces apoptosis in organotypic hippocampal slice cultures. *Brain Research*, **2003**, 964, 264-78	3.7	66
10	The GABAA receptor agonist THIP is neuroprotective in organotypic hippocampal slice cultures. *Brain Research*, **2003**, 973, 303-6	3.7	22
9	3-Nitropropionic acid neurotoxicity in hippocampal slice cultures: developmental and regional vulnerability and dependency on glucose. *Experimental Neurology*, **2002**, 176, 237-46	5.7	12
8	Biocompatibility of silicon-based arrays of electrodes coupled to organotypic hippocampal brain slice cultures. *Brain Research*, **2001**, 896, 1-17	3.7	67
7	The metabotropic glutamate receptor agonist 1S,3R-ACPD stimulates and modulates NMDA receptor mediated excitotoxicity in organotypic hippocampal slice cultures. *Brain Research*, **2001**, 898, 91-104	3.7	25
6	Comparison of excitotoxic profiles of ATPA, AMPA, KA and NMDA in organotypic hippocampal slice cultures. *Brain Research*, **2001**, 917, 21-44	3.7	97
5	GDNF and neublastin protect against NMDA-induced excitotoxicity in hippocampal slice cultures. *NeuroReport*, **2000**, 11, 4069-73	1.7	35
4	Excitotoxic effects of non-NMDA receptor agonists in organotypic corticostriatal slice cultures. *Brain Research*, **1999**, 841, 143-59	3.7	47
3	Markers for neuronal degeneration in organotypic slice cultures. *Brain Research Protocols*, **1999**, 3, 278-90		249
2	Coupling of organotypic brain slice cultures to silicon-based arrays of electrodes. *Methods*, **1999**, 18, 160-72	4.6	31
1	Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner		1